Objective: The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19. Methods: We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated. Results: Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3-2.95 vs median, 0.82 nmol/L; interquartile range, 0.57-1.03; P <.0001). Receiver operating characteristic curve analysis showed good accuracy of MR-proADM for predicting mortality. A MR-proADM value of 1.73 nmol/L was established as the best cutoff value, with 90% sensitivity and 95% specificity (P <.0001). Conclusion: We found that MR-proADM could represent a prognostic biomarker of COVID-19.

Lo Sasso, B., Gambino, C.M., Scichilone, N., Giglio, R.V., Bivona, G., Scazzone, C., et al. (2021). Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19. LABORATORY MEDICINE, 52(5), 493-498 [10.1093/labmed/lmab032].

Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19

Lo Sasso, Bruna;Gambino, Caterina Maria;Scichilone, Nicola;Giglio, Rosaria Vincenza;Bivona, Giulia;Scazzone, Concetta;Muratore, Roberto;Milano, Salvatore;Barbagallo, Mario;Agnello, Luisa;Ciaccio, Marcello
2021-09-01

Abstract

Objective: The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19. Methods: We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated. Results: Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3-2.95 vs median, 0.82 nmol/L; interquartile range, 0.57-1.03; P <.0001). Receiver operating characteristic curve analysis showed good accuracy of MR-proADM for predicting mortality. A MR-proADM value of 1.73 nmol/L was established as the best cutoff value, with 90% sensitivity and 95% specificity (P <.0001). Conclusion: We found that MR-proADM could represent a prognostic biomarker of COVID-19.
1-set-2021
https://academic.oup.com/crawlprevention/governor?content=/labmed/article-lookup/doi/10.1093/labmed/lmab032
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600477/
Lo Sasso, B., Gambino, C.M., Scichilone, N., Giglio, R.V., Bivona, G., Scazzone, C., et al. (2021). Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19. LABORATORY MEDICINE, 52(5), 493-498 [10.1093/labmed/lmab032].
File in questo prodotto:
File Dimensione Formato  
Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19.pdf

Solo gestori archvio

Tipologia: Post-print
Dimensione 174.55 kB
Formato Adobe PDF
174.55 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
lmab032.pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 123.8 kB
Formato Adobe PDF
123.8 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/517229
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 1
social impact